Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer
Authors: Lu Shun , Zhang Wei , Wu Lin , Wang Wenxiang , Zhang Peng ,   Neotorch Investigators, Fang Wentao , Xing Wenqun , Chen Qixun , Yang Lin , Mei Jiandong , Tan Lijie , Sun Xiaohong , Xu Shidong , Hu Xiaohua , Yu Guohua , Yu Dongliang , Yang Nong , Chen Yuping , Shan Jinlu , Xing Ligang , Tian Hui , Zhang Xun , Zhou Ming , Fang Haohui , Wu Guowu , Liu Yunpeng , Ye Minhua , Cao Lejie , Jiang Jie , Li Xingya , Zhu Liangming , Li Shanqing , Kang Mingqiang , Zhong Aihong , Chen Keneng , Wu Nan , Sun Qian , Ma Haitao , Cai Kaican , Wang Changli , Lin Gen , Zhu Kunshou , Zhang Yu , Zhang Xiaochun , Hu Hong , Zhang Wengang , Chen Jun , Yang Zhixiong , Hang Xiaosheng , Hu Jian , Huang Yunchao , Zhang Zhiye , Zhang Lumin , Zhang Liwei , Liu Lunxu , Lin Dongmei , Zhang Jie , Chen Gang , Li Yuan , Zhu Lei , Wang Weihua , Yu Wenbo , Cao Dezhen , Keegan Patricia , Yao Sheng 
Published: January 2024

Importance

Adjuvant and neoadjuvant immunotherapy have improved clinical outcomes for patients with early-stage non–small cell lung cancer (NSCLC). However, the optimal combination of checkpoint inhibition with chemotherapy remains unknown.

Objective

To determine whether toripalimab in combination with platinum-based chemotherapy will improve event-free survival and major pathological response in patients with stage II or III resectable NSCLC compared with chemotherapy alone.

Design, Setting, and Participants

This randomized clinical trial enrolled patients with stage II or III resectable NSCLC (without EGFR or ALK alterations for nonsquamous NSCLC) from March 12, 2020, to June 19, 2023, at 50 participating hospitals in China. The data cutoff date for this interim analysis was November 30, 2022.

Interventions

Patients were randomized in a 1:1 ratio to receive 240 mg of toripalimab or placebo once every 3 weeks combined with platinum-based chemotherapy for 3 cycles before surgery and 1 cycle after surgery, followed by toripalimab only (240 mg) or placebo once every 3 weeks for up to 13 cycles.

Main Outcomes and Measures

The primary outcomes were event-free survival (assessed by the investigators) and the major pathological response rate (assessed by blinded, independent pathological review). The secondary outcomes included the pathological complete response rate (assessed by blinded, independent pathological review) and adverse events.

Results

Of the 501 patients randomized, 404 had stage III NSCLC (202 in the toripalimab + chemotherapy group and 202 in the placebo + chemotherapy group) and 97 had stage II NSCLC and were excluded from this interim analysis. The median age was 62 years (IQR, 56-65 years), 92% of patients were male, and the median follow-up was 18.3 months (IQR, 12.7-22.5 months). For the primary outcome of event-free survival, the median length was not estimable (95% CI, 24.4 months-not estimable) in the toripalimab group compared with 15.1 months (95% CI, 10.6-21.9 months) in the placebo group (hazard ratio, 0.40 [95% CI, 0.28-0.57], P &amp;lt; .001). The major pathological response rate (another primary outcome) was 48.5% (95% CI, 41.4%-55.6%) in the toripalimab group compared with 8.4% (95% CI, 5.0%-13.1%) in the placebo group (between-group difference, 40.2% [95% CI, 32.2%-48.1%], P &amp;lt; .001). The pathological complete response rate (secondary outcome) was 24.8% (95% CI, 19.0%-31.3%) in the toripalimab group compared with 1.0% (95% CI, 0.1%-3.5%) in the placebo group (between-group difference, 23.7% [95% CI, 17.6%-29.8%]). The incidence of immune-related adverse events occurred more frequently in the toripalimab group. No unexpected treatment-related toxic effects were identified. The incidence of grade 3 or higher adverse events, fatal adverse events, and adverse events leading to discontinuation of treatment were comparable between the groups.

Conclusions and Relevance

The addition of toripalimab to perioperative chemotherapy led to a significant improvement in event-free survival for patients with resectable stage III NSCLC and this treatment strategy had a manageable safety profile.

Trial Registration

ClinicalTrials.gov Identifier: NCT04158440